Lung cancer, which is considered as the deadliest cancer, takes lakhs of lives every year.
Sotorasib, the new Amgen drug has bring a new ray of hope in this field.
U.S. food and administration has approved this drug for small cell lung cancer, which will be sold under the brand name Lumakras. Patients having small cell lung cancers with the KRAS mutation, non-small lung cancer with KRASG12C mutation, and some colorectal and other type of cancers will be benefitted via this; because chemotherapy and other medicines didn’t show expected results in treating these.
The company officials assured that the drug can have U.S. list price of $17,900 per month